Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 46Multiple Myeloma 45Lymphoma 43Neoplasm Metastasis 40Breast Neoplasms 38Lung Neoplasms 37Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 30Leukemia, Myeloid, Acute 28Colorectal Neoplasms 28Melanoma 27Ovarian Neoplasms 25Hematologic Neoplasms 22Urinary Bladder Neoplasms 21Pancreatic Neoplasms 21Lymphoma, Non-Hodgkin 20Glioma 20Carcinoma, Renal Cell 19Sarcoma 18Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Myelodysplastic Syndromes 15Burkitt Lymphoma 15Neuroblastoma 14Lymphoma, Large B-Cell, Diffuse 13Fallopian Tube Neoplasms 13Ependymoma 13Carcinoma 13Brain Neoplasms 13Thyroid Neoplasms 12

Interventions

Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hearing Loss × 30 days × Clear all
NCT04915183 2026-05-22

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡